AIML subsidiary NeuralCloud Solutions Inc., Signs Non-Binding Commercial Term Sheet with Lakeshore Cardiology to Deploy CardioYield(TM) for AI-Powered Holter Analysis

Executive Summary

• AI/ML Innovations Inc. (AIML) announced a commercial agreement term sheet with Lakeshore Cardiology to integrate NeuralCloud’s CardioYield™ AI‑driven Holter monitoring platform into the clinic’s workflow.
• The partnership will begin with internal validation, proceed to a limited paid trial, and move toward full cloud‑based deployment pending Health Canada clearance.
• The collaboration expands NeuralCloud’s presence in ambulatory cardiac monitoring and positions CardioYield™ for broader clinical adoption.

Key Details

• Parties Involved: NeuralCloud Solutions Inc. (subsidiary of AIML) and Lakeshore Cardiology, a fully accredited cardiac facility in Toronto.
• Agreement Scope: Staged rollout – internal validation → limited paid trial → full integration and cloud deployment; commercial availability contingent on Health Canada approval.
• Product Highlights:
• CardioYield™ AI visualization platform powered by MaxYield™ signal‑processing engine.
• Automated detection and labeling of P waves, QRS complexes, T waves; beat‑by‑beat interval data for downstream analytics.
• User‑friendly interface with automated grouping of conditions/abnormalities and end‑to‑end Holter report generation.
• Strategic Intent: Streamline ECG data review, accelerate clinical decision‑making, and provide consistent interpretation across Holter monitoring workflows.
• Quotes:
• Esmat Naikyar (President, NeuralCloud & CPO, AIML) – emphasized commitment to AI‑driven ECG analysis in clinical practice.
• Martina Magnotta (Operations Manager, Lakeshore Cardiology) – highlighted potential for faster interpretation and improved patient care.
• Paul Duffy (Executive Chairman & CEO, AIML) – noted the partnership’s role in expanding AI platform adaptability across clinical environments.

Notable Quotes

• “This agreement with Lakeshore Cardiology highlights NeuralCloud's commitment to bringing AI‑driven ECG analysis into clinical practice.” – Esmat Naikyar
• “CardioYield™ can potentially help our team quickly interpret cardiac signals, enhancing the quality of care for our patients.” – Martina Magnotta
• “By bringing MaxYield™ and CardioYield™ into the Holter monitoring workflow, we're helping redefine the standard for ECG analysis in real‑world clinical practice.” – Paul Duffy

Materiality Assessment

• Non‑Material – Positive – The announcement is a forward‑looking partnership without disclosed financial terms or immediate revenue impact, but it signals a positive strategic development for the company.